BR112021026411A2 - Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos - Google Patents

Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos

Info

Publication number
BR112021026411A2
BR112021026411A2 BR112021026411A BR112021026411A BR112021026411A2 BR 112021026411 A2 BR112021026411 A2 BR 112021026411A2 BR 112021026411 A BR112021026411 A BR 112021026411A BR 112021026411 A BR112021026411 A BR 112021026411A BR 112021026411 A2 BR112021026411 A2 BR 112021026411A2
Authority
BR
Brazil
Prior art keywords
lrrc25
compositions
methods
myeloid cell
cell phenotypes
Prior art date
Application number
BR112021026411A
Other languages
English (en)
Portuguese (pt)
Inventor
Brian O'nuallain
Igor Feldman
A Wahle Joseph
L Sazinsky Stephen
I Novobrantseva Tatiana
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of BR112021026411A2 publication Critical patent/BR112021026411A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112021026411A 2019-06-27 2020-06-17 Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos BR112021026411A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867593P 2019-06-27 2019-06-27
PCT/US2020/038115 WO2020263650A1 (en) 2019-06-27 2020-06-17 Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (1)

Publication Number Publication Date
BR112021026411A2 true BR112021026411A2 (pt) 2022-03-15

Family

ID=74060354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026411A BR112021026411A2 (pt) 2019-06-27 2020-06-17 Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos

Country Status (10)

Country Link
US (1) US20220363752A1 (https=)
EP (1) EP3990017A4 (https=)
JP (1) JP2022539038A (https=)
KR (1) KR20220042131A (https=)
CN (1) CN114423452A (https=)
AU (1) AU2020306772A1 (https=)
BR (1) BR112021026411A2 (https=)
CA (1) CA3142838A1 (https=)
IL (1) IL289166A (https=)
WO (1) WO2020263650A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267340A1 (en) * 2022-10-05 2024-04-11 Shangpharma Innovation, Inc. Anti-urokinase type plasminogen activator receptor antibodies and methods of use
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101122628B1 (ko) * 2009-02-16 2012-04-12 한국화학연구원 노닐페놀에 의해 유도된 생식독성 진단용 바이오마커 및 이를 이용한 생식독성 진단 방법
US10279018B2 (en) * 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
WO2016203053A2 (en) * 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017004153A1 (en) * 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
JP7078533B2 (ja) * 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物
CN109313201B (zh) * 2016-06-14 2022-04-01 高级生物设计公司 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
JP2021529753A (ja) * 2018-06-29 2021-11-04 ヴェルソー セラピューティクス， インコーポレイテッド 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法

Also Published As

Publication number Publication date
EP3990017A4 (en) 2023-04-26
AU2020306772A1 (en) 2022-02-17
EP3990017A1 (en) 2022-05-04
CN114423452A (zh) 2022-04-29
JP2022539038A (ja) 2022-09-07
US20220363752A1 (en) 2022-11-17
IL289166A (en) 2022-02-01
WO2020263650A1 (en) 2020-12-30
CA3142838A1 (en) 2020-12-30
KR20220042131A (ko) 2022-04-04

Similar Documents

Publication Publication Date Title
BR112021026181A2 (pt) Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112021024314A2 (pt) Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112021024242A2 (pt) Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112022023892A2 (pt) Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos
WO2022109339A8 (en) Use of dextramer in single cell analysis
MY209123A (en) Compositions, methods and systems for protein corona analysis and uses thereof
WO2018234793A3 (en) Antibodies
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
MY202395A (en) Gremlin-1 crystal structure and inhibitory antibody
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2023014389A (es) Anticuerpos anti-sirp-alfa.
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
WO2019136300A3 (en) Anti-mct1 antibodies and uses thereof
BR112021026411A2 (pt) Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
WO2017062496A3 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
MY205041A (en) Variant rnai
EP4512830A3 (en) Antibodies useful in cancer diagnosis
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t
PH12022553181A1 (en) Anti-pd-1 antibodies
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
Ménoret et al. Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.